Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Genomics Gains CLIA Certification in Three More States

NEW YORK (GenomeWeb News) – MicroRNA diagnostics company Rosetta Genomics said today that it has received Clinical Laboratory Improvement Amendments certification in three states.

The Rehovot, Israel-based company said that it has passed the survey for CLIA certification in California, Rhode Island, and Maryland to conduct molecular diagnostic tests at its Rosetta Laboratories, bringing the total number of states from which it has received CLIA certification to 48.

The company also said in financial statements filed with the US Securities and Exchange Commission that it could receive up to $17 million from San Diego-based Prometheus Laboratories for research and development, milestone and other payments, and from royalties from the sale of its tests.

Prometheus licensed the US rights to Rosetta Genomics' miRView mets, miRview squamous, and miRview Meso tests in April, and it took an equity stake in the company. Rosetta Genomics said in the SEC filing that Prometheus purchased 2 million of its ordinary shares for $8 million.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.